Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen (NASDAQ:AMGN) has announced its quarterly dividend for the first quarter of 2025. The company's Board of Directors has declared a dividend of $2.38 per share. Shareholders who are recorded as stockholders by the close of business on February 14, 2025, will receive the dividend payment on March 7, 2025.
Amgen's BLINCYTO (blinatumomab) has shown significant improvement in disease-free survival when added to chemotherapy for newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). In a Phase 3 study, the three-year disease-free survival rate was 96.0% for patients receiving BLINCYTO plus chemotherapy, compared to 87.9% for chemotherapy alone, representing a 61% reduction in disease relapse risk.
The study met its primary endpoint early, leading to early termination of randomization due to clear benefits. For standard-risk average patients, three-year survival was 97.5% with BLINCYTO versus 90.2% with chemotherapy alone. For high-risk patients, rates were 94.1% versus 84.8%. Safety results aligned with BLINCYTO's known profile, showing minimal severe side effects.
Amgen (NASDAQ: AMGN) has announced a $1 billion expansion to establish a second drug substance manufacturing facility in Holly Springs, North Carolina. This investment builds upon a previous $550 million commitment, bringing the total planned investment to over $1.5 billion.
The expansion will create 370 new jobs in the region and incorporate cutting-edge technologies and sustainable practices. The new facility, alongside the existing one, will strengthen Amgen's global biomanufacturing network and support the company's ability to meet growing demand for its innovative therapies.
Amgen (NASDAQ:AMGN) has announced its participation in Citi's 2024 Global Healthcare Conference on Thursday, Dec. 5, 2024, at 9:30 a.m. ET. The company will be represented by three executive leaders: Peter Griffith (EVP and CFO), Jay Bradner (EVP of R&D and CSO), and Susan Sweeney (EVP of Obesity and Related Conditions), who will engage in a fireside chat.
The presentation will be webcast live and made accessible to investors, media, and the public through Amgen's website. The webcast recording will remain available for replay on www.amgen.com under the Investors section for at least 90 days following the event.
Amgen (NASDAQ:AMGN) has announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 10:00 a.m. ET. Three executive leaders will participate in a fireside chat: Peter Griffith (EVP and CFO), Jay Bradner (EVP of Research and Development, CSO), and Susan Sweeney (EVP of Obesity and Related Conditions).
The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast will remain available for replay for at least 90 days following the event.
Amgen (NASDAQ:AMGN) reported positive 52-week Phase 2 study results for MariTide, a monthly or less frequent subcutaneous treatment for obesity. The drug achieved ~20% average weight loss in people with obesity/overweight without Type 2 diabetes, and ~17% weight loss in those with Type 2 diabetes, alongside a 2.2 percentage point reduction in HbA1c. No weight loss plateau was observed, suggesting potential for further weight reduction. The treatment showed improvements in cardiometabolic parameters and had manageable gastrointestinal side effects. The discontinuation rate in dose escalation arms was ~11%. Amgen announced the initiation of MARITIME, a Phase 3 program for obesity and related conditions.
Amgen (NASDAQ:AMGN) announced a webcast scheduled for November 26, 2024, at 5 a.m. PT to discuss the results of their 52-week Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and its development program progress. The presentation will feature CEO Robert A. Bradway and other senior management team members. The webcast will be accessible to investors, media, and the public through Amgen's website, with replay available for at least 90 days after the event.
Amgen (NASDAQ:AMGN) has appointed Howard Chang, M.D., Ph.D. as senior vice president of Research and chief scientific officer, effective December 16, 2024. Reporting to Jay Bradner, executive vice president of R&D, Chang will lead research priorities across rare disease, oncology, inflammation, and cardiometabolic therapeutic areas. He will oversee operations in research hubs from San Francisco to Thousand Oaks, and across global sites in Reykjavik, Copenhagen, Munich, British Columbia, and Maryland. Chang succeeds Ray Deshaies, Ph.D., whose departure was announced earlier this year.
Amgen presented new data for its rare disease treatments at ACR 2024, highlighting significant results for UPLIZNA and KRYSTEXXA. The MITIGATE Phase 3 study showed UPLIZNA reduced IgG4-RD flare risk by 87% compared to placebo, with 57.4% of patients achieving flare-free complete remission at Week 52. The AGILE trial demonstrated that KRYSTEXXA with methotrexate administered in 60-minute infusions maintained efficacy, with 67.2% of participants achieving target urate levels. The FDA granted Breakthrough Therapy Designation for UPLIZNA in IgG4-RD, and regulatory filings are underway for both treatments.
Amgen (NASDAQ:AMGN) has released a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, formerly AMG 133). The company affirms there is no apparent connection between MariTide administration and bone mineral density changes. Amgen maintains that the Phase 1 study results do not indicate any bone safety concerns and do not affect their confidence in MariTide's potential. The company plans to release Phase 2 topline data later this year.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
